微信直播

AME新书《泌尿肿瘤》译者招募

Published at: 2015年第1卷第S1期

关键词:

泌尿系统肿瘤是指发生于泌尿系统任意部位的肿瘤。包括肾、肾盂、输尿管、膀胱、尿道肿瘤。泌尿系统肿瘤是泌尿外科领域中最常见的疾病之一,且其发病率和死亡率呈增长趋势。在此背景下,AME出版社邀请复旦大学附属肿瘤医院泌尿外科主任叶定伟教授担任主编出版了英文专著Urinary system tumor.

本书由来自美国、中国、意大利等14个国家的知名高校、科研机构、医学中心共177名泌尿外科领域专家学者参与编写。全书共分为泌尿系肿瘤的生物学、诊断和治疗三大板块,治疗部分又从手术治疗、化学治疗、放射治疗和多学科综合治疗四个方面进行综合论述,是一本覆盖面广、专业性强的实用书籍。

AME将同步发行本书的中文版《泌尿肿瘤》,现诚邀国内外该领域优秀医学工作者参与本书的翻译工作!

此专题待翻译文章目录如下,欢迎各位认领:

1. Androgen receptor gene mutation,rearrangement,polymorphism

2. Androgen receptor epigenetics

3. Androgen receptor genomic regulation

4. Decoding the androgen receptor splice variants

5. Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation

6. Novel non-AR therapeutic targets in castrate resistant prostate cancer

7. Steroid hormone synthetic pathways in prostate cancer

8. Translating insights of AR signaling from mouse models

9. Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression

10. The role of microRNAs in prostate cancer progression

11. Cancer stem cells in prostate cancer

12. Bacille-Calmette-Guerin non-responders:how to manage

13. TGF-β mediated DNA methylation in prostate cancer

14. Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET/CT:preliminary report of in six patients

15. Prostate cancer magnetic resonance imaging (MRI):multidisciplinary standpoint

16. The current and future role of magnetic resonance imaging in prostate cancer detection and management

17. Utility of ADC measurement on diffusion-weighted MRI in differentiation of prostate cancer,normal prostate and prostatitis

18. Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer

19. Standard cystectomy fits all:truth or myth?

20. Outlining the limits of partial nephrectomy

21. Penile rehabilitation after radical prostatectomy:does it work?

22. Cytoreductive surgery in the era of targeted molecular therapy

23. Presentation,management,and outcomes of complications following prostate cancer therapy

24. Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer

25. Radiotherapy for prostate cancer and sexual health

26. Stereotactic body radiotherapy for organ-confined prostate cancer

27. Proton beam radiation therapy of prostate cancer-history,results,and future directions

28. Impact of comorbidity in elderly prostate cancer patients treated with brachytherapy

29. Current clinical challenges in prostate cancer

30. Sequence of treatment in locally advanced and metastatic renal cell carcinoma

31. Advances in the treatment of testicular cancer

32. Upper urinary tract disease:what we know today and unmet needs

33. Indications for biopsy and the current status of focal therapy for renal tumours

34. Active surveillance and focal therapy for low-intermediate risk prostate cancer

35. Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer

36. Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

37. Surgery and hormonal treatment for prostate cancer and sexual function

38. Challenges to treat hypogonadism in prostate cancer patients:implications for endocrinologists, urologists and radiotherapists

39. Role of hormonal therapy for prostate cancer: perspective from Japanese experiences

40. How to evaluate sexual health in cancer patients:development of the EORTC sexual health questionnaire for cancer patients

41. Pharmacologic and surgical therapies for sexual dysfunction in male cancer survivors

42. Co-constructing sexual recovery after prostate cancer:a qualitative study with couples

43. Couples-based interventions following prostate cancer treatment:a narrative review

44. The argument for palliative care in prostate cancer

45. Prevention of bone metatasis in prostate cancer by denosumab:Unneeded endpoint or unmet need?

46. Contemporary and future insights into fertility preservation in male cancer patients

47. A second opportunity to come for anti-angiogenics in prostate cancer?

48. Treatment of localized prostate cancer in elderly patients

49. The primary health care physician and the cancer patient:tips and strategies for managing sexual health

50. Future perspectives of prostate cancer therapy

认领方法:

  1. 下载译者报名表(http://rlxt.amegroups.cn/#notices/9),填写完毕后发送到:rlxt@amegroups.com

  2. 编辑部会综合选择最匹配的专家参与翻译,并给符合要求的专家注册系统账号和获取稿件等信息;

  3. 每位会员/译者认领的书籍和文章均不得超过3本/3篇,编辑部将会对超出译者做出适当的调整;

  4. 注:凡是通过编辑部审核并注册系统账号的专家,我们将会在系统委员风采上展示您的个人风采(包括姓名,科室和简介)

  • 认领截止日期:本次认领长期有效,直至认领完毕。

  • 认领成功后,请在认领成功后的三周内将翻译稿及个人简介上传到系统;并发送到rlxt@amegroups.com

凡翻译质量通过审核的译者,可获得:

  1. 每翻译一篇文章,即可获得价值200元人民币的科研时间积分(200快币),可换购各种图书/杂志,免费登录视频数据库ASVIDE,观看手术视频(积分限免)。

  2. 译者署名权。

  3. 中文版出版后,获赠新书一本。

主编风采:

叶定伟  教授,主任医师,博士生导师

叶定伟教授从事医教研25年,具有丰富的泌尿系统肿瘤综合治疗经验。擅长泌尿男生殖系统肿瘤早期诊断、根治手术和综合治疗,尤其擅长前列腺癌、膀胱癌和肾癌的根治性手术。1996年9月至1998年12月在美国MD Anderson癌症中心学习,系统掌握泌尿男性生殖系统肿瘤国际规范的手术和提高肿瘤生存率的综合治疗方法。两次入选中华医学会泌尿外科学会“将才工程”计划赴美国学习,享受国务院特殊政府津贴。担任复旦大学附属肿瘤医院副院长、泌尿外科主任,泌尿男生殖系统肿瘤多学科协作诊治中心首席专家,复旦大学泌尿外科研究所副所长,复旦大学前列腺肿瘤诊治研究中心主任,上海市泌尿外科学会副主任委员上海市抗癌协会理事长,中国抗癌协会泌尿肿瘤专业委员会候任主任委员。

comments powered by Disqus

附件